Avalyn Pharma Inc. (AVLN) Stock Forecast
AVLN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $61.80 average of analyst targets
- Upside to target
- +161.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.64
- 52-week range
- $23.66 – $39.25
AVLN analyst ratings
5 analystsNumber of analysts at each rating.
AVLN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AVLN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.75 | −$0.79 | −$0.71 | — | — | 2 |
| Current fiscal year (2026) | −$2.69 | −$2.69 | −$2.69 | — | — | 1 |
| Next fiscal year (2027) | −$2.58 | −$2.58 | −$2.58 | −$2.69 | +4.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AVLN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
AVLN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AVLN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.58 | −$0.79 | −$0.79 | −$0.79 | −$0.75 | +28.2% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.94 | −$1.94 | −$1.94 | −$1.94 | −$2.69 | +38.7% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.90 | −$1.90 | −$1.90 | −$1.90 | −$2.58 | +35.8% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AVLN earnings surprises
Reported EPS vs the consensus estimate for the last 2 quarters; AVLN beat in 1 of 2.
What analysts expect from AVLN
5 analysts cover Avalyn Pharma; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $61.80, 161.2% above the latest close of $23.66. Analysts expect earnings of −$2.69 per share for 2026. For 2027 the average estimate is −$2.58 per share. Avalyn Pharma beat the EPS estimate in 1 of the last 2 quarters.
Related: AVLN income statement, AVLN key metrics, AVLN chart. See the AVLN stock overview for the latest quote and news.
AVLN forecast FAQ
What is Avalyn Pharma's price target?
The average analyst price target for Avalyn Pharma is $61.80, 161.2% above the latest close of $23.66.
Is Avalyn Pharma a buy, hold or sell?
Of 5 analysts covering Avalyn Pharma, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Avalyn Pharma's EPS forecast?
Analysts forecast −$2.69 per share for 2026 (range −$2.69 to −$2.69); for 2027 the estimate is −$2.58.
When does Avalyn Pharma report earnings?
Avalyn Pharma is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.64.
Does Avalyn Pharma usually beat earnings estimates?
Avalyn Pharma reported EPS at or above the analyst estimate in 1 of the last 2 quarters.